Study of NanoKnife for Ablation of Prostate Cancer in Intermediate Risk Patients

Prostate Cancer Clinical Trial

Official title:

A Pilot Study in Human Subjects Evaluating the Use of the NanoKnife System for Ablation of Prostate Cancer Tissue in an Intermediate Risk Patient Population

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01972867
• Other study ID #: ON-NK310
• Status: Active, not recruiting
• Phase: N/A
• Start date: May 13, 2021
• Est. completion date: May 2024

Study information

• Verified date: January 2023
• Source: Angiodynamics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the feasibility and short-term safety and effectiveness of the NanoKnife System when used to ablate localized prostate cancer in intermediate risk subjects with organ-confined prostate cancer. This study will evaluate the feasibility of the NanoKnife System as a focal therapy.

Description:

This study will involve six (6) subjects who meet the intermediate risk prostate cancer criteria defined by this protocol. The biopsy and imaging techniques that we will adopt within this trial are multiparametric MRI (mpMRI) and transperineal prostate biopsy (template mapping and/or limited targeted). The subjects' prostate cancer foci, the location of which will be determined by ultrasound guided transperineal prostate biopsy, will be targeted for treatment with the NanoKnife System. The primary objective of this the study will be to evaluate procedural and short-term post treatment safety of the NanoKnife treatment via incidence of adverse events and evaluation of effect on urologic (urinary and erectile) function. The secondary objective of this study is to evaluate the short term efficacy of the NanoKnife treatment. Local efficacy in the area of treatment will be assessed by histological evaluation of transperineal prostate biopsy cores at six (6) months post NanoKnife treatment, to evaluate the ablation zone created by the NanoKnife treatment. Other secondary outcomes include health-related quality of life levels evaluated using validated patient questionnaires. Following the 6 month transperineal prostate biopsy and mpMRI assessment, the data from these 6 subjects will be submitted to FDA for confirmation of short term safety and efficacy.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 6
• Est. completion date: May 2024
• Est. primary completion date: November 1, 2022
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Has at least a 10-year life expectancy

2. Have histologically confirmed organ-confined prostate cancer - clinical Stage = T2c

3. Have a PSA = 15 ng/mL or PSA density < 0.15 ng/mL2 if PSA is > 15 ng/mL

4. Has Gleason score 3+4 or 4+3

5. Has 10 mm or less of cancer-bearing prostate tissue in any biopsy core

6. No evidence of extraprostatic extension or seminal vesicle invasion by mpMRI

7. Able to visualize prostate gland adequately on transrectal ultrasound imaging during enrollment evaluation

8. Transperineal targeted prostate biopsies of lesion, plus 12 core systematic biopsies to include adequate sampling of the peripheral zone correlating with an intermediate risk lesion in the area of the MR-visible lesion.

9. A visible lesion on mpMRI that is accessible to Irreversible Electroporation (IRE) treatment

10. A non-MRI visible lesion detected via systematic standard biopsy will not be considered an exclusion condition provided the non-MRI visible lesion is singularly located in the contralateral hemisphere of the prostate; is Gleason 6; and comprises no more than 6mm linear extent of cancer-bearing tissue in a single core on standard biopsy.

11. Must sign a written informed consent

12. Understands and accepts the obligation and is logistically able to present for all scheduled follow-up visits

Exclusion Criteria:

1. Have known hypersensitivity to pancuronium bromide, atricurium or cisatricurium

2. Unfit for anesthesia or have a contraindication for agents listed for paralysis

3. Have an active urinary tract infection (UTI)

4. Have a history of bladder neck contracture

5. Are interested in future fertility

6. Have a history (within 3 years) of inflammatory bowel disease

7. Have a concurrent major debilitating illness

8. Had a malignancy within 5 years, including malignant melanoma, except for prostate cancer or other types of skin cancer

9. Have any active implanted electronic device (e.g., pacemaker)

10. Are unable to catheterize due to a urethral stricture disease

11. Have had prior or current prostate cancer therapies:

1. Biologic therapy for prostate cancer

2. Chemotherapy for prostate cancer

3. Hormonal therapy for prostate cancer within three months of procedure

4. Radiotherapy for prostate cancer

5. Surgery for prostate cancer

12. Have had prior transurethral prostatectomy (TURP), stricture surgery, urethral stent or prostatic implants

13. Have had prior major rectal surgery (except hemorrhoids)

14. Unfit for pelvic MRI scanning (e.g., severe claustrophobia, permanent cardiac pacemaker, metallic implants that are likely to contribute significant image artifacts, allergy or contraindication to gadolinium (to enhance MRI)

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Device:
• NanoKnife Procedure
Subjects will be placed in the dorsal lithotomy position, under sterile technique. The NanoKnife procedure will be carried out under general anesthesia. A Foley catheter will be placed to aid in draining the bladder during treatment.

Locations

Country	Name	City	State
United States	Rush University Medical Center	Chicago	Illinois
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Angiodynamics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment procedural and short-term post-treatment safety profile	To determine the NanoKnife treatment procedural and short-term post-treatment safety profile by evaluating adverse event incidence, type, duration, severity and relationship to study device.	6 months
Primary	Treatment Morbidity Profile	To determine the NanoKnife treatment morbidity profile by evaluating urinary and erectile function.	6 months
Secondary	Completeness of Ablation	To determine completeness of ablation in the targeted prostate cancer tissue, in relation to probe placement and treatment parameters applied, as determined by histological evaluation of transperineal prostate biopsy cores at six (6) months post- treatment.; Determine post-treatment PSA kinetics; Determine effectiveness of therapy by post-treatment imaging (necrosis, presence of residual tissue); Determine effectiveness of therapy by rates of biochemical and clinical progression; need for secondary or adjuvant treatment	6 months
Secondary	Prostate-Specific Antigen Kinetics	Determine post-NanoKnife treatment prostate-specific antigen (PSA) kinetics including time to PSA nadir and post-nadir PSA stability.	24 months
Secondary	Effectiveness of Therapy	To determine the effectiveness of therapy by post-treatment early-contrast MRI and multiparametric magnetic resonance imaging (mpMRI) to evaluate the area of necrosis and presence of residual tissue.	24 months
Secondary	Effectiveness of Therapy	To determine the effectiveness of therapy by recording the rates of biochemical and clinical progression and the need for secondary or adjuvant treatment following therapy.	24 months
Secondary	Health-Related Quality of Life	To determine health-related quality of life (HRQoL) levelsafter NanoKnife using validated patient questionnaires.	24 months